MetaVia Inc.
NASDAQMTVA heads into its May 18 earnings print carrying one of the most expensive borrow costs in the biotech universe — a signal that short-side pressure, while not dominant by position size, is punishingly costly to maintain. Borrowing MTVA shares costs nearly 200% annualised. The cost to borrow has held above 199% for weeks, easing only modestly from a peak above 270%…
MTVA short interest
Full pulse commentary is for ORTEX subscribers. The live data picture for MTVA below stays open — short interest, options flow, signals, and historical context.
Sign up free to read pulse →Short interest % of float, cost to borrow, utilization, and put/call ratio for MTVA are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 15 May 2026
MTVA heads into its May 18 earnings print carrying one of the most expensive borrow costs in the biotech universe — a signal that short-side pressure, while not dominant by position size, is punishingly costly to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MTVA — free to start on ORTEX.
Sign up for free →Open MTVA on ORTEX